Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.
Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
June 2, 1998
Assignees:
Cor Therapeutics, The Regents of the University of California
Inventors:
Shaun R. Coughlin, Robert M. Scarborough
Abstract: A (injectable biologically active) polypeptide is stabilized by dissolving said polypeptide forming a liquid solution in citrate buffer of about pH 5.0-5.5.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
May 5, 1998
Assignee:
COR Therapeutics
Inventors:
Robert L. Swift, Charles P. Du Mee, Anne Randolph